The Effect of Rifaximin on Portal Vein Thrombosis (ERPVT)

Fudan University

Status

Unknown

Conditions

Cirrhosis

Portal Vein Thrombosis

Treatments

Drug: Rifaximin

Study type

Interventional

Funder types

Other

Identifiers

NCT03631147

CSY-RFXM-PVT

Details and patient eligibility

About

The aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal vein thrombosis in cirrhotic patients

Full description

Portal vein thrombosis is not an uncommon complication in cirrhotic portal hypertension, which lead to a poor prognosis in endoscopic management of variceal bleeding. Evidence indicated that enoxaparin prevented PVT and liver decompensation via decreased rates of bacterial infections and lowered the potent inflammatory mediators such as interleukin-6. Rifaximin is a broad-spectrum antibiotic that exerts endotoxin-lowering and anti-inflammatory effects.

Enrollment

96 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 y.o. ≤age≤75 y.o
Cirrhotic patients had CTA confirmed portal vein trombosis
D-dimer no more than five times the normal upper limit

Exclusion criteria

age <18 y.o. or age > 75 y.o.
had portal cavernoma
received anticoagulation treatment in the past 6 months
splenectomy
Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)
Massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics.
Acute variceal bleeding within 5 days.
Use of other antibiotics in the past 2 weeks
Acute portal vein thrombosis